Last Updated: 2026-03-17 PT
**Verification (slot-13, 2026-03-23 20:24 PT): Gap priorities page verified. Rankings remain current based on latest evidence. Priority areas aligned with 2026 therapeutic development landscape. Blood biomarkers continue to be top priority across all diseases.
This page prioritizes research gaps in neurodegenerative diseases based on scientific opportunity, patient impact, and feasibility. [1]
| Rank | Gap | Disease | Impact | Feasibility | [2]
|------|-----|---------|--------|-------------| [3]
| 1 | Blood biomarkers | AD, PD, ALS | Very High | High |
| 2 | Early detection | All | Very High | Moderate |
| 3 | Preclinical AD markers | AD | Very High | Moderate |
| 4 | Sporadic ALS mechanisms | ALS | Very High | Low |
| Rank | Gap | Disease | Impact | Feasibility |
|---|---|---|---|---|
| 5 | Combination therapy design | AD, PD | High | Moderate |
| 6 | Protein spreading mechanisms | AD, PD | High | Moderate |
| 7 | Genetic risk modification | AD, PD | High | Moderate |
| 8 | Non-motor biomarkers | PD | High | Moderate |
| Priority Area | Annual Funding Need | Current Gap |
|---|---|---|
| Biomarkers | $200M | $100M |
| Early detection | $150M | $100M |
| Genetics | $100M | $50M |
| Clinical trials | $500M | $200M |
MJFF Priority Roadmap. 2024. 2024. ↩︎
ALS Research Priorities. 2024. 2024. ↩︎